These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 21906584)

  • 21. Pharmacokinetics of treosulfan in pediatric patients undergoing hematopoietic stem cell transplantation.
    Ten Brink MH; Ackaert O; Zwaveling J; Bredius RG; Smiers FJ; den Hartigh J; Lankester AC; Guchelaar HJ
    Ther Drug Monit; 2014 Aug; 36(4):465-72. PubMed ID: 24487253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Home administration of high-dose oral busulfan in patients undergoing hematopoietic stem cell transplantation.
    Matthews RH; Emami M; Connaghan DG; Holland HK; Morris LE
    Bone Marrow Transplant; 2007 Apr; 39(7):397-400. PubMed ID: 17322933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of busulfan area under the curve with veno-occlusive disease following BMT.
    Dix SP; Wingard JR; Mullins RE; Jerkunica I; Davidson TG; Gilmore CE; York RC; Lin LS; Devine SM; Geller RB; Heffner LT; Hillyer CD; Holland HK; Winton EF; Saral R
    Bone Marrow Transplant; 1996 Feb; 17(2):225-30. PubMed ID: 8640171
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of Limited Sampling Methods for Oral Busulfan Pharmacokinetic Monitoring in Adult Patients Undergoing Hematopoietic Stem Cell Transplantation.
    Bouchard P; Bilodeau S; Alain K; Vadnais B; Franco M; Turgeon J; Michaud V
    Ther Drug Monit; 2016 Jun; 38(3):414-8. PubMed ID: 26829598
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of existing limited sampling models for busulfan kinetics in children with beta thalassaemia major undergoing bone marrow transplantation.
    Balasubramanian P; Chandy M; Krishnamoorthy R; Srivastava A
    Bone Marrow Transplant; 2001 Nov; 28(9):821-5. PubMed ID: 11781641
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dosing algorithm revisit for busulfan following IV infusion.
    Wang Y; Kato K; Le Gallo C; Armstrong E; Rock E; Wang X
    Cancer Chemother Pharmacol; 2015 Mar; 75(3):505-12. PubMed ID: 25561350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Busulfan dosing algorithm and sampling strategy in stem cell transplantation patients.
    de Castro FA; Piana C; Simões BP; Lanchote VL; Della Pasqua O
    Br J Clin Pharmacol; 2015 Oct; 80(4):618-29. PubMed ID: 25819742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Age-dependent tetrahydrothiophenium ion formation in young children and adults receiving high-dose busulfan.
    Gibbs JP; Murray G; Risler L; Chien JY; Dev R; Slattery JT
    Cancer Res; 1997 Dec; 57(24):5509-16. PubMed ID: 9407960
    [TBL] [Abstract][Full Text] [Related]  

  • 29. I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients.
    Nguyen L; Fuller D; Lennon S; Leger F; Puozzo C
    Bone Marrow Transplant; 2004 May; 33(10):979-87. PubMed ID: 15064687
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determination of area under the whole blood concentration versus time curve after first intravenous cyclosporine dose in children undergoing hematopoietic stem cell transplant: limited sampling strategies.
    Sibbald C; Seto W; Taylor T; Saunders EF; Doyle J; Dupuis LL
    Ther Drug Monit; 2008 Aug; 30(4):434-8. PubMed ID: 18641547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa).
    Bouligand J; Boland I; Valteau-Couanet D; Deroussent A; Kalifa C; Hartmann O; Vassal G
    Bone Marrow Transplant; 2003 Nov; 32(10):979-86. PubMed ID: 14595385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of a Test Dose Strategy for Pharmacokinetically-Guided Busulfan Dosing for Hematopoietic Stem Cell Transplantation.
    Davis JM; Ivanova A; Chung Y; Shaw JR; Rao KV; Ptachcinski JR; Sharf AA; Serody JS; Armistead PM; Wood WA; Coghill JM; Jamieson KJ; Vincent BG; Riches ML; Shea TC; Alexander MD
    Biol Blood Marrow Transplant; 2019 Feb; 25(2):391-397. PubMed ID: 30244102
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients.
    Malär R; Sjöö F; Rentsch K; Hassan M; Güngör T
    Pediatr Transplant; 2011 Sep; 15(6):580-8. PubMed ID: 21736681
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [High-dose busulfan--monitoring plasma levels and dosage adjustments in adults].
    Kalous O; Mayer J; Malásková L
    Cas Lek Cesk; 2001 Nov; 140(23):724-8. PubMed ID: 11787234
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral busulfan pharmacokinetics and engraftment in children with Hurler syndrome and other inherited metabolic storage diseases undergoing hematopoietic cell transplantation.
    Jacobson P; Park JJ; DeFor TE; Thrall M; Abel S; Krivit W; Peters C
    Bone Marrow Transplant; 2001 Apr; 27(8):855-61. PubMed ID: 11477444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity.
    Zwaveling J; Bredius RG; Cremers SC; Ball LM; Lankester AC; Teepe-Twiss IM; Egeler RM; den Hartigh J; Vossen JM
    Bone Marrow Transplant; 2005 Jan; 35(1):17-23. PubMed ID: 15502853
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trough level monitoring of intravenous busulfan to estimate the area under the plasma drug concentration-time curve in pediatric hematopoietic stem cell transplant recipients.
    Watanabe E; Nishikawa T; Ikawa K; Yamaguchi H; Abematsu T; Nakagawa S; Kurauchi K; Kodama Y; Tanabe T; Shinkoda Y; Matsumoto K; Okamoto Y; Takeda Y; Kawano Y
    Int J Hematol; 2015 Nov; 102(5):611-6. PubMed ID: 26243625
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease.
    McPherson ME; Hutcherson D; Olson E; Haight AE; Horan J; Chiang KY
    Bone Marrow Transplant; 2011 Jan; 46(1):27-33. PubMed ID: 20305698
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Re: intravenous versus oral busulfan--perhaps not as different as suggested.
    Slattery JT
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):282-4. PubMed ID: 12720221
    [No Abstract]   [Full Text] [Related]  

  • 40. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.
    Bleyzac N; Souillet G; Magron P; Janoly A; Martin P; Bertrand Y; Galambrun C; Dai Q; Maire P; Jelliffe RW; Aulagner G
    Bone Marrow Transplant; 2001 Oct; 28(8):743-51. PubMed ID: 11781625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.